PMID- 10648423
OWN - NLM
STAT- MEDLINE
DCOM- 20000224
LR  - 20131121
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 95
IP  - 3
DP  - 2000 Feb 1
TI  - Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage
      leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23).
PG  - 1066-8
AB  - The mixed lineage leukemia (MLL) gene located at chromosome band 11q23 is
      frequently rearranged in patients with therapy-related acute monocytic leukemia
      who received topoisomerase II inhibitors. We have identified a novel fusion
      partner of MLL (FAB M5b) in a patient who developed t-AML 9 years after treatment
      for acute lymphoblastic leukemia (ALL). The leukemic cells had a sole karyotypic 
      abnormality of t(3;11) (p21;q23). Screening of a genomic DNA library, prepared
      from leukemic cell DNA, identified rearranged clones composed of MLL and a novel 
      gene on chromosome 3p21 (AF3p21). The AF3p21 gene encodes a protein of 722 amino 
      acids, which contains an Src homology 3 (SH3) domain, a proline-rich domain, and 
      a bipartite nuclear localizing signal (NLS). RNA analysis demonstrated that exon 
      6 of the MLL gene fused to exon 2 of the AF3p21 gene. The resulting chimeric
      protein consists of AT-hooks, methyltransferase, and transcription repressor
      domains of MLL in addition to the AF3p21 proline-rich domain and NLS but not the 
      AF3p21 SH3 domain.
FAU - Sano, K
AU  - Sano K
AD  - Department of Pediatrics, Kobe University School of Medicine, Kobe, Japan.
      sanoped@kobe-u.ac.jp
FAU - Hayakawa, A
AU  - Hayakawa A
FAU - Piao, J H
AU  - Piao JH
FAU - Kosaka, Y
AU  - Kosaka Y
FAU - Nakamura, H
AU  - Nakamura H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (AF3p21-MLL fusion protein, human)
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (DNA, Complementary)
RN  - 0 (Muscle Proteins)
RN  - 0 (NCKIPSD protein, human)
RN  - 0 (Nitrosourea Compounds)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - RYH2T97J77 (ranimustine)
RN  - ZS7284E0ZP (Daunorubicin)
SB  - AIM
SB  - IM
MH  - *Adaptor Proteins, Signal Transducing
MH  - Adolescent
MH  - Amino Acid Sequence
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Base Sequence
MH  - Bone Marrow Transplantation
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage/adverse effects
MH  - DNA, Complementary/genetics
MH  - Daunorubicin/administration & dosage/adverse effects
MH  - Etoposide/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Leukemia, Monocytic, Acute/chemically induced/drug therapy/*genetics/therapy
MH  - Leukemia-Lymphoma, Adult T-Cell/drug therapy
MH  - Molecular Sequence Data
MH  - *Muscle Proteins
MH  - Myeloid-Lymphoid Leukemia Protein
MH  - Neoplasms, Second Primary/chemically induced/drug therapy/*genetics/therapy
MH  - Nitrosourea Compounds/administration & dosage/adverse effects
MH  - Nuclear Proteins/*genetics
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Sequence Alignment
MH  - Sequence Homology, Nucleic Acid
MH  - src Homology Domains/*genetics
EDAT- 2000/01/29 09:00
MHDA- 2000/02/26 09:00
CRDT- 2000/01/29 09:00
PHST- 2000/01/29 09:00 [pubmed]
PHST- 2000/02/26 09:00 [medline]
PHST- 2000/01/29 09:00 [entrez]
PST - ppublish
SO  - Blood. 2000 Feb 1;95(3):1066-8.